This article is more than 5 years old. Information may no longer be current.
Top stories in endocrinology: Study results demonstrate CV-neutral effect with linagliptin in diabetes, real-world HbA1c reduction with liraglutide matches large clinical trial
Click Here to Manage Email Alerts
Among the top stories in endocrinology is an announcement that a trial involving the DPP-IV linagliptin produced positive top-line results and demonstrated similar CV safety vs. placebo in adults with type 2 diabetes and high CV risk. Researchers observed similar reductions in HbA1c associated with use of liraglutide despite differences typically seen between large randomized and controlled trial populations and real-world cohorts. Other top stories include a two-screen approach to diagnostic testing for congenital hypothyroidism in newborns that identified missed cases of the disease, a wearable device that measures how much cortisol a person is producing through sweat, and a study indicating that most older breast cancer survivors who were prescribed anti-estrogen therapy did not undergo the recommended bone density screening to monitor the effects of treatments on osteoporosis risk.
CARMELINA results demonstrate CV neutral effect with linagliptin in diabetes
Researchers with the CARMELINA cardiovascular outcomes trial announced positive top-line results for the DPP-IV inhibitor linagliptin, noting the drug demonstrated similar CV safety vs. placebo in adults with type 2 diabetes and high CV risk, according to a press release from Boehringer Ingelheim and Eli Lilly. Read More.
Real-world HbA1c reduction with liraglutide matches large clinical trial
Despite differences typically seen between large randomized controlled trial populations and real-world cohorts, researchers observed similar reductions in HbA1c associated with use of liraglutide, according to findings published in Diabetes Care. Read More.
In newborns, two-screen approach better identifies congenital hypothyroidism
A two-screen approach to diagnostic testing for congenital hypothyroidism, performed in newborns during the first 48 hours after birth and again at age 7 to 28 days, better identified missed cases of the disease vs. lowering the diagnostic threshold for a single test, according to an analysis published this week in the CDC’s Morbidity and Mortality Weekly Report. Read More.
Wearable patch measures cortisol in sweat
Researchers from Stanford University have designed a wearable device that measures how much cortisol a person is producing through sweat, according to a press release from the university. Read More.
Bone density screenings ‘suboptimal’ among older breast cancer survivors
Most older breast cancer survivors prescribed anti-estrogen therapy do not undergo the recommended bone density screening to monitor the effects of treatments on osteoporosis risk, according to a database analysis published in Bone. Read More.